Clinical trials: pMMR
Rectal Cancer, Moderately Hypofractionated Radiotherapy
Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Multi-center Randomized Control Phase II Trial
This study aims to observe and evaluate the efficacy and safety of moderately hypofractionated radiotherapy combined with chemotherapy and immunotherapy, compared with conventional neoadjuvant chemoradiotherapy, in patients with…
- Conditions
- Rectal Cancer, Moderately Hypofractionated Radiotherapy, Serplulimab, pMMR/MSS
- Trial name
- NCT07527520
- Testing
- Moderately Hypofractionated Radiotherapy, Serplulimab, CapOx+Long-course radiotherapy
- Where
- China
- Volunteers
- 165 people
- Sponsor
- Fudan University
Endometrial Carcinoma (EC), pMMR
IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER
Endometrial carcinoma (EC) represents the most common gynecological malignancy in developed countries. Despite therapeutic advances, patients with advanced or recurrent disease still have a poor prognosis, with high recurrence…
- Conditions
- Endometrial Carcinoma (EC), pMMR, DMMR Cancer
- Trial name
- DEMETER (NCT07374809)
- Testing
- DNA methylation profiles
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- European Institute of Oncology
Colorectal Cancer
A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment
The goal of this clinical trial is to explore the preliminary efficacy and tolerability of Aipalolitovorelizumab (QL1706) in combination with fruquintinib for the treatment of metastatic colorectal cancer patients with…
- Trial name
- NCT07229872
- Testing
- Aipalolitovorelizumab, Fruquintinib
- Volunteers
- 18 people
- Sponsor
- Harbin Medical University
Colorectal Cancer With Liver Metastasis
A Prospective Multicenter Study: Ivosimab + Chemotherapy as Neoadjuvant for Resectable pMMR/MSS CRC Liver Mets
The population receiving ivosimab combined with chemotherapy for neoadjuvant treatment of colorectal cancer liver metastasis.
- Trial name
- NCT06972498
- Testing
- Patients will receive ivosimab combined with the XELOX/FOLFOX regimen, followed by radical surgery 4-6 weeks after the last dose; adjuvant chemotherapy will continue for 3 months postoperatively.
- Volunteers
- 35 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Rectal Cancer
Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study
The objective is to evaluate whether the neoadjuvant combination of tislelizumab (a PD-1 inhibitor) with interleukin-2 (IL-2) chemotherapy can significantly increase the Objective Response Rate (ORR) and the Pathological Complete…
- Trial name
- NCT06884670
- Testing
- Interleukin-2, Radiotherapy, Tislelizumab
- Where
- 4 sites in China
- Volunteers
- 130 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Locally Recurrent Rectal Cancer
Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer
TORCH-R2 is a prospective, multicenter, randomized, phase II clinical trial. Patients aged 18 years or older with pelvic recurrence rectal cancer without synchronous distant metastases or recent chemo- and/or radiotherapy…
- Trial name
- NCT06928584
- Testing
- Conventional Radiotherapy, Capecitabine, 5-fluorouracil
- Where
- China
- Volunteers
- 221 people
- Sponsor
- Fudan University
Rectal Cancer, Radiation
SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer
Primary Objectives： Evaluate the complete response rate (CR rate) and safety of short - course radiotherapy combined with ivonesimab (AK112) in patients with pMMR/MSS mid - low rectal cancer.
- Conditions
- Rectal Cancer, Radiation, AK112
- Trial name
- STAR (NCT07162714)
- Testing
- radiotherapy, Ivonescimab (20mg/kg Q3W), Non-operative Management
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Rectal Adenocarcinoma, High-Risk Cancer
SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC
To explore the efficacy and safety of an intensified treatment regimen consisting of short-course radiotherapy followed by mFOLFOX6 chemotherapy combined with precise targeted therapy (based on RAS/BRAF status: cetuximab for…
- Conditions
- Rectal Adenocarcinoma, High-Risk Cancer, MSS
- Trial name
- CRITⅡ (NCT07549399)
- Testing
- Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Solid Tumor Cancer, Adult Refractory Cancer
Study of GV20-0251 in Participants With Solid Tumor Malignancies
This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
- Conditions
- Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
- Trial name
- NCT07070518
- Testing
- GV20-0251
- Where
- 3 sites in China
- Volunteers
- 350 people
- Sponsor
- GV20 Therapeutics
Rectal Adenocarcinoma
A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer
The purpose of this study is to evaluate the efficacy and safety of short-course radiotherapy followed by ivonescimab and chemotherapy in participants with pMMR/MSS locally advanced rectal cancer.
- Trial name
- NCT06919510
- Testing
- lvonescimab, CAPOX (oxaliplatin/capecitabine), radiotherapy
- Volunteers
- 90 people
- Sponsor
- Sun Yat-sen University
Metastatic Colorectal Cancer (CRC), MSS Metastatic Colorectal Cancer
Multicenter Retrospective Study on Optimizing Combination Immunotherapy Strategies in MSS/MSI-L/pMMR Advanced Colorectal Cancer
This multicenter retrospective study aims to evaluate and optimize combination immunotherapy strategies for patients with microsatellite stable (MSS), microsatellite instability-low (MSI-L), or mismatch repair-proficient (pMMR)…
- Conditions
- Metastatic Colorectal Cancer (CRC), MSS Metastatic Colorectal Cancer, Immunotherapy
- Trial name
- NCT06849362
- Testing
- Bevacizumab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Yue Gou
Rectal Cancer
Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy
The goal of this Phase 2 trial is to evaluate a neoadjuvant treatment mode for locally advanced rectal cancer (LARC), consisting of radiotherapy and concurrent Trifluridine/Tipiracil (TAS-102).
- Trial name
- TASLARC (NCT05965531)
- Testing
- Trifluridine/Tipiracil, intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Sun Yat-sen University
Metastatic Colorectal Cancer
- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
This is a prospective, randomized, open-label, multicenter phase II investigating the therapy of Fruquintinib in combination with Tislelizumab in patients with MSS/pMMR metastatic colorectal cancer without liver metastases.
- Trial name
- NCT06856837
- Testing
- Fruquintinib, Tislelizumab, Trifluridine/tipiracil
- Where
- 23 sites in Austria, Germany
- Volunteers
- 140 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Mismatch Repair-proficient, Colorectal Cancer Metastatic
Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer
Explore the efficacy of radiotherapy combined with Tislelizumab and irinotecan in MSS/pMMR inoperable recurrent and metastatic colorectal cancer patients; To evaluate the safety and tolerability of radiotherapy combined with…
- Conditions
- Mismatch Repair-proficient, Colorectal Cancer Metastatic, Microsatellite Stable
- Trial name
- NCT05160727
- Testing
- Tislelizumab, Irinotecan, radiotherapy
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Zhejiang Cancer Hospital
Locally Advanced Rectal Cancer
Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune Score
This is a prospective, one arm phase II study aimed to observe the efficacy and safety of tislelizumab combined with fruquintinib in treatment of patients with pMMR / MSS locally advanced rectal cancer with high immune score.
- Trial name
- NCT04989855
- Testing
- Fruquintinib plus Tislelizumab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University
Locally Advanced Rectal Cancer
A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer
In pMMR/MSS locally advanced rectal cancer, can the innovative "chemo-immunotherapy induction + LCRT + chemo-immunotherapy consolidation" approach significantly improve the complete response rate and create opportunities for…
- Trial name
- NCT07527026
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Chinese PLA General Hospital
Advanced Colorectal Cancer
A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer
This study is an open label, multicenter Phase II clinical trial aimed at evaluating the safety and efficacy of JS207 with or without JS015 in combination with chemotherapy (XELOX) as a first-line treatment for advanced…
- Trial name
- NCT06885385
- Testing
- JS207, JS015, Capecitabine
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Colorectal Cancer Metastatic
Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis
This is a non-randomized, open-label, single-center clinical trial to evaluate efficacy and safety of sintilimab plus bevacizumab and chemotherapy on treatment in patients with advanced no liver metastatic MSS/pMMR colorectal…
- Trial name
- NCT06973343
- Testing
- Group A, Group B
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Anhui Provincial Cancer Hospital
Colorectal Cancer
Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal Cancer
Immune checkpoint inhibitor (ICI) treatment has produced striking results in patients with colorectal cancer (CRC) of the subtype deficient mismatch repair (dMMR).
- Trial name
- FLU-IMMUNE (NCT05909423)
- Testing
- Influenza vaccine, Pembrolizumab
- Where
- Denmark
- Volunteers
- 21 people
- Sponsor
- Zealand University Hospital
Metastatic Colorectal Cancer
Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases
The goal of this clinical trial is to evaluate the superiority of ivonescimab combined with FOLFIRI over FOLFIRI + bevacizumab as second-line treatment of non resectable pMMR/MSS BRAFwt mCRC patients without liver metastases in…
- Trial name
- COLIBRI-GI (NCT07359456)
- Testing
- Ivonescimab, Bevacizumab, FOLFIRI Protocol
- Where
- 22 sites in France
- Volunteers
- 130 people
- Sponsor
- UNICANCER